Identification
- Summary
Technetium Tc-99m pyrophosphate is a radiopharmaceutical diagnostic agent used for diagnostic imaging scans for the bones, heart, and gastrointestinal tract.
- Generic Name
- Technetium Tc-99m pyrophosphate
- DrugBank Accession Number
- DB09165
- Background
A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Technetium Tc-99m pyrophosphate (DB09165)
- Weight
- Average: 272.847
Monoisotopic: 272.81818089 - Chemical Formula
- O7P2Tc
- Synonyms
- Technetium (99mTc) pyrophosphate
- Technetium TC 99M Pyrophosphate
Pharmacology
- Indication
For use as a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction Label. May also be used to image gated blood pools and detect gastrointetinal bleeding.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Technetium Tc-99m pyrophosphate collects in areas of altered osteogenesis and injured myocardium. It also has an affinity for red blood cells, enabling imaging of blood pools.
- Mechanism of action
It is thought that technetium Tc-99m pyrophosphate is adsorbed onto the surface of amorphous calcium phosphate deposits 1, insoluble hydroxyapatite crystals, and possibly other organic macromolecules. This would result in selective localization to necrotic muscle tissue such as that of a myocardial infarction where calcium deposition has begun as a result of cell damage. In areas of altered osteogenesis where hydroxyapatite formation is actively occuring, the surface area to volume ratio is high and favors a greater amount of technetium Tc-99m pyrophosphate to the surface of the crystals than in other areas of bone where crystal formation is less active. The localization of technetium Tc-99m pyrophosphate to these areas allows for their specific radioimaging.
Target Actions Organism NHydroxyapatite ligandHumans NAmorphous calcium phosphate ligandHumans - Absorption
1-2h after injection approximately 40-50% is localized to the skeleton and 0.01-0.02% per gram to acutely infarcted myocardium Label.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Approximately 40% of the dose is excreted in the urine within 24h Label.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Adverse reactions such as flushing, hypotension, fever, chills, nausea, vomiting and dizziness, as well as hypersensitivity reactions such as itching and various skin rashes have been noted Label. Technetium Tc-99m pyrophosphate is a radiopharmaceutical and carries the risk of radiation toxicity if inappropriately dosed.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Technetium Tc-99m pyrophosphate which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Aclidinium Aclidinium may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Acrivastine Technetium Tc-99m pyrophosphate may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Kit for the Preparation of Technetium Tc99m Pyrophosphate Injection 12 mg/10mL Intravenous Sun Pharmaceutical Industries, Inc. 1987-06-30 Not applicable US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Technescan PYP Technetium Tc-99m pyrophosphate (11.9 mg/10mL) + Stannous chloride dihydrate (3.2 mg/10mL) Injection, powder, lyophilized, for solution Intravenous Mallinckrodt 2009-03-20 2017-07-01 US
Categories
- ATC Codes
- V09BA03 — Technetium (99mtc) pyrophosphate
- Drug Categories
- Acids
- Acids, Noncarboxylic
- Compounds used in a research, industrial, or household setting
- Diagnostic Radiopharmaceuticals
- Diagnostic Uses of Chemicals
- Diphosphates
- Drugs that are Mainly Renally Excreted
- Indicators and Reagents
- Laboratory Chemicals
- Phosphate salts
- Phosphoric Acids
- Phosphorus Acids
- Phosphorus Compounds
- Polyphosphates
- Radioactive Diagnostic Agent
- Radiopharmaceutical Activity
- Radiopharmaceuticals
- Skeleton
- Technetium (99Mtc) Compounds
- Technetium Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as transition metal pyrophosphates. These are inorganic compounds in which the largest oxoanion is pyrophosphate, and in which the heaviest atom not in an oxoanion is a transition metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Transition metal oxoanionic compounds
- Sub Class
- Transition metal pyrophosphates
- Direct Parent
- Transition metal pyrophosphates
- Alternative Parents
- Inorganic salts / Inorganic oxides
- Substituents
- Inorganic oxide / Inorganic salt / Transition metal pyrophosphate
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 5L76I61H2B
- CAS number
- 52997-54-3
- InChI Key
- OOGKGVXDDGJCPO-NLQOEHMXSA-J
- InChI
- InChI=1S/H4O7P2.Tc/c1-8(2,3)7-9(4,5)6;/h(H2,1,2,3)(H2,4,5,6);/q;+4/p-4/i;1+2
- IUPAC Name
- (99Tc)technetium(4+) ion (phosphonooxy)phosphonate
- SMILES
- [99Tc+4].[O-]P([O-])(=O)OP([O-])([O-])=O
References
- General References
- Buja LM, Tofe AJ, Kulkarni PV, Mukherjee A, Parkey RW, Francis MD, Bonte FJ, Willerson JT: Sites and mechanisms of localization of technetium-99m phosphorus radiopharmaceuticals in acute myocardial infarcts and other tissues. J Clin Invest. 1977 Sep;60(3):724-40. [Article]
- External Links
- FDA label
- Download (104 KB)
- MSDS
- Download (28.3 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intravenous 12 mg/10mL Injection, powder, lyophilized, for solution Intravenous Kit - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Soluble MSDS Radioactivity (mCi/mL) 2 FDA Label - Predicted Properties
Property Value Source Water Solubility 10.8 mg/mL ALOGPS logP 1.43 ALOGPS logP -1.4 Chemaxon logS -1.6 ALOGPS pKa (Strongest Acidic) 1.7 Chemaxon Physiological Charge -3 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 135.61 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 21.04 m3·mol-1 Chemaxon Polarizability 9.03 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Targets
References
- Buja LM, Tofe AJ, Kulkarni PV, Mukherjee A, Parkey RW, Francis MD, Bonte FJ, Willerson JT: Sites and mechanisms of localization of technetium-99m phosphorus radiopharmaceuticals in acute myocardial infarcts and other tissues. J Clin Invest. 1977 Sep;60(3):724-40. [Article]
References
- Buja LM, Tofe AJ, Kulkarni PV, Mukherjee A, Parkey RW, Francis MD, Bonte FJ, Willerson JT: Sites and mechanisms of localization of technetium-99m phosphorus radiopharmaceuticals in acute myocardial infarcts and other tissues. J Clin Invest. 1977 Sep;60(3):724-40. [Article]
Drug created at October 05, 2015 17:05 / Updated at October 09, 2021 02:48